Clinical Trials Logo
  1. Home
  2. Stage III Melanoma
  3. NCT02794636

Interferon Toxicities in Melanoma Treatment — ITMT  

Stage III Melanoma Clinical Trial

Official title:
Analysis of the Clinical and Economic Impact of Adverse Events and Medication-related Toxicities Associated With Interferon (IFN) Treatment for Patients With Stage III Melanoma

Clinical Trial Summary

The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting. A secondary objective is to quantify annual costs and resource utilization before and after IFN initiation among patients with stage III melanoma in a real-world setting.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02794636
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase N/A
Start date May 2014
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Terminated NCT01875653 - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Phase 3
Terminated NCT01026051 - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma Phase 2
Completed NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Phase 1/Phase 2
Active, not recruiting NCT05079113 - Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
Terminated NCT00082875 - Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma Phase 2
Completed NCT00003789 - Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg Phase 3
Active, not recruiting NCT03719131 - Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Phase 2
Completed NCT01376713 - Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma Phase 2
Completed NCT00450255 - VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 2
Completed NCT00119249 - Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Phase 2
Terminated NCT00087386 - Tanespimycin in Treating Patients With Stage III-IV Melanoma Phase 2
Recruiting NCT03385486 - Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors Phase 1
Completed NCT02073123 - Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Phase 1/Phase 2
Recruiting NCT01168050 - Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. Phase 2
Terminated NCT00945269 - Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma Phase 1/Phase 2
Completed NCT00217542 - Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery Phase 1
Completed NCT00089362 - Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Phase 1
Completed NCT00003647 - Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma Phase 3
Completed NCT04059224 - TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma Phase 2